Literature DB >> 25271596

The indirect costs of psoriatic arthritis: systematic review and meta-analysis.

Paweł Kawalec1, Krzysztof Piotr Malinowski.   

Abstract

The aim of this systematic review is to collect all current data on the indirect costs (IC) related to psoriatic arthritis (PsA). The search was conducted using MEDLINE (via PubMed), Embase and Centre for Reviews and Dissemination databases. We considered original studies, systematic reviews, economic evaluations, conference abstracts and posters. All collected data were recalculated to average annual cost per patient, expressed using the consumer price index for 2013 and converted to US dollars using purchasing power parity. Eight of the identified publications presented IC of PsA. Average annual IC per patient calculated using the friction cost approach range from US$1693.83 to $12,318.45, while using the human capital approach they range from US$1750.68 to $50,270.52. Result of the meta-analysis was a basis for calculating cost of work disability equaled US$10,754.04 per patient per year in 2013 prices. This systematic review revealed a great economic burden of the disease to the society. A small number of studies on IC in PsA justify further investigations.

Entities:  

Keywords:  absenteeism; cost of illness; economic burden; indirect cost; presenteeism; psoriatic arthritis; sick leave; systematic review

Mesh:

Year:  2014        PMID: 25271596     DOI: 10.1586/14737167.2015.965154

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  6 in total

1.  Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA.

Authors:  Joseph F Merola; Vivian Herrera; Jacqueline B Palmer
Journal:  Clin Rheumatol       Date:  2018-07-26       Impact factor: 2.980

2.  The national economic burden of rare disease in the United States in 2019.

Authors:  Grace Yang; Inna Cintina; Anne Pariser; Elisabeth Oehrlein; Jamie Sullivan; Annie Kennedy
Journal:  Orphanet J Rare Dis       Date:  2022-04-12       Impact factor: 4.123

3.  Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.

Authors:  Vibeke Strand; Elaine Husni; Jenny Griffith; Zheng-Yi Zhou; James Signorovitch; Arijit Ganguli
Journal:  Rheumatol Ther       Date:  2016-09-15

4.  Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland.

Authors:  Paweł Kawalec; Krzysztof Piotr Malinowski; Andrzej Pilc
Journal:  Rheumatol Int       Date:  2016-06-23       Impact factor: 2.631

5.  Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.

Authors:  Adeline Ruyssen-Witrand; Richard Perry; Clare Watkins; George Braileanu; Gayathri Kumar; Sandeep Kiri; Debby Nott; Soyi Liu-Leage; Susanne Hartz; Christophe Sapin
Journal:  RMD Open       Date:  2020-02

6.  Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain.

Authors:  Bernd Schweikert; Chiara Malmberg; Mercedes Núñez; Tatiana Dilla; Christophe Sapin; Susanne Hartz
Journal:  BMJ Open       Date:  2020-08-13       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.